Worldwide Clinical Trials
JUNE 15, 2022
We’ve also seen a decrease in available research nurses, as they have had to be reassigned to COVID patients. There have been a few cases lately where patients receiving gene therapy had a severe adverse effect because of their immune response to the mechanism of the AAV viral vector, based on their own genomic markers.
The Pharma Data
JANUARY 24, 2021
National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes. Quantum Genomics launched its Phase III REFRESH trial in difficult-to-treat or resistant hypertension.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
AUGUST 11, 2020
1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. It is not known whether OPDIVO or YERVOY is present in human milk.
The Pharma Data
AUGUST 11, 2020
1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. It is not known whether OPDIVO or YERVOY is present in human milk.
The Pharma Data
JANUARY 13, 2021
health officials have about containing the coronavirus in the coming months, U.S. Right now, the vaccines are largely being distributed to people in the highest-risk categories, including frontline health care workers and older people and staff in nursing homes. In a change that illustrates the level of worry U.S. ” The U.S.
Expert insights. Personalized for you.
130 
Let's personalize your content